[C-11]Thymidine has been shown to be a sensitive and specific agent for observing tumor response to treatment. The radiopharmaceutical for PET imaging is designed to provide quantitative data on tumor DNA synthetic rate. We have incorporated imaging and blood sampling data into kinetic models od DNA metabolism that are used to generate parametric images of thymidine flux rate in tumor. Following our substantial progress in validating this procedure, we will use [C-11]thymidine as a tool to observe tumor response in cancer therapy.
In Specific Aim 1 a, patients with brain tumors undergoing standard therapy will be studied. The extent of tumor penetration into normal brain will be determined with thymidine flux images. These images will distinguish between abnormalities seen on MR or CT imaging due to blood-brain disruption and proliferative tumor extension. Imaging with [F-18]FDG will provide a comparison between tumor metabolism and proliferation.
Specific Aim 2 will measure changes in tumor proliferation in patients with breast cancer undergoing chemotherapy using [c-11]thymidine. Chemotherapeutic agents are highly effective for a percentage of patients but are extremely toxic. The timing and extent of response are unknown. This group of patients will be imaged with [C- 11]thymidine before and after treatment to: 1) profile responders by correlation of thymidine uptake with tumor biopsy and 2) observe the time- course of change in thymidine uptake in responding and on-responding patients. As in Aim 1, FDG images will be obtained at the same timepoints to compare tumor metabolism and proliferation measured with thymidine. Using [C-11]thymidine in association with [F-18]FDG and assays on biopsy material, we will gain valuable insight into the extent and magnitude of response of brain tumors and breast cancer to treatment strategies. PET metabolic imaging with these agents can make comprehensive tumor assessments in vivo over time and will contribute to better patient management as well as better understanding of tumor biology.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA042045-14
Application #
6300263
Study Section
Project Start
2000-03-01
Project End
2001-02-28
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
14
Fiscal Year
2000
Total Cost
$280,798
Indirect Cost
Name
University of Washington
Department
Type
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Lindner, Jonathan R; Link, Jeanne (2018) Molecular Imaging in Drug Discovery and Development. Circ Cardiovasc Imaging 11:e005355
O'Sullivan, Finbarr; O'Sullivan, Janet N; Huang, Jian et al. (2018) Assessment of a statistical AIF extraction method for dynamic PET studies with 15O water and 18F fluorodeoxyglucose in locally advanced breast cancer patients. J Med Imaging (Bellingham) 5:011010
Linden, Hannah M; Peterson, Lanell M; Fowler, Amy M (2018) Clinical Potential of Estrogen and Progesterone Receptor Imaging. PET Clin 13:415-422
Link, Jeanne M; Krohn, Kenneth A; O'Hara, Matthew J (2017) A simple thick target for production of89Zr using an 11MeV cyclotron. Appl Radiat Isot 122:211-214
Wolsztynski, E; O'Sullivan, F; O'Sullivan, J et al. (2017) Statistical assessment of treatment response in a cancer patient based on pre-therapy and post-therapy FDG-PET scans. Stat Med 36:1172-1200
Kurland, Brenda F; Peterson, Lanell M; Lee, Jean H et al. (2017) Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer. Clin Cancer Res 23:407-415
Wangerin, Kristen A; Muzi, Mark; Peterson, Lanell M et al. (2017) A virtual clinical trial comparing static versus dynamic PET imaging in measuring response to breast cancer therapy. Phys Med Biol 62:3639-3655
Fowler, Amy M; Clark, Amy S; Katzenellenbogen, John A et al. (2016) Imaging Diagnostic and Therapeutic Targets: Steroid Receptors in Breast Cancer. J Nucl Med 57 Suppl 1:75S-80S
Muzi, Mark; Krohn, Kenneth A (2016) Imaging Hypoxia with ยน?F-Fluoromisonidazole: Challenges in Moving to a More Complicated Analysis. J Nucl Med 57:497-8
Currin, Erin; Peterson, Lanell M; Schubert, Erin K et al. (2016) Temporal Heterogeneity of Estrogen Receptor Expression in Bone-Dominant Breast Cancer: 18F-Fluoroestradiol PET Imaging Shows Return of ER Expression. J Natl Compr Canc Netw 14:144-7

Showing the most recent 10 out of 196 publications